Cholesterol-lowering drugs could reduce brown fat linked to weight loss

ETH Zurich scientists have shown that statins, one of the most commonly prescribed classes of pharmaceuticals, reduce beneficial brown adipose tissue.

But this is no reason to demonize these drugs, the researchers insist.

A certain proportion of the adult population has not only white adipose (or fatty) tissue, but also the brown kind. This brown adipose tissue helps to convert sugar and fat into heat.

People with brown adipose tissue are better at regulating their body temperature in the winter, and are less likely to suffer from excess weight or diabetes.

An international team of researchers led by ETH Zurich has now discovered that the statin class of pharmaceuticals reduces the formation of brown adipose tissue.

Statins are prescribed as a way to reduce the risk of a heart attack since they reduce cholesterol levels in the blood. They are among the most commonly prescribed drugs worldwide.

The researchers have been researching brown adipose tissue for many years.

They looked into the question of how “bad” white fat cells, which form the layer of fat under our skin, become “good” brown fat cells.

Having conducted cell culture experiments, they found out that the biochemical pathway responsible for producing cholesterol plays a central role in this transformation.

They also discovered that the key molecule regulating the transformation is the metabolite geranylgeranyl pyrophosphate.

Earlier studies showed that the cholesterol biochemical pathway is also central to the functioning of statins; one of their effects is to reduce the production of geranylgeranyl pyrophosphate.

This is why the researchers wanted to know whether statins also impact the formation of brown adipose tissue. And indeed they do, as the scientists have now shown in studies on mice and humans.

One thing the researchers did was study positron emission tomography scans of 8,500 patients at the University Hospital Zurich.

This let them determine whether the person had brown adipose tissue. It was also known whether the patients were taking statins.

Evaluating the scans shows that 6 percent of those not taking the medication had brown adipose tissue, but this tissue type was present in only a little over 1 percent of those who were taking statins.

The researchers conducted a separate clinical study of 16 people at the University Hospitals of Basel and Zurich to demonstrate that statins reduce the activity of brown adipose tissue.

Although the study demonstrated that statins have a negative impact, the team warns against talking them down.

However, statins also have another negative effect: in high doses, they slightly increase some people’s risk of developing diabetes – as has been shown in other studies.

But the team stresses that even if such a link were established, that would be no reason to demonize statins.

Rather, it would become imperative to conduct further research into the mechanisms behind this and find out which patients are affected.

It might then be possible to take a personalized medicine approach and continue to recommend statins to most people, while proposing alternative therapies for a small group of patients.

Written by Fabio Bergamin.

Source: ETH Zurich.